DUBLIN--(BUSINESS WIRE)--The "Global Therapeutic vaccine Market - Segmented by Type, and Geography - Growth, Trends and Forecasts (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
In 2017, the global therapeutic vaccine market was valued at around USD 14.15 billion. North America accounted for the highest market value in 2017, however Middle East & Africa is expected to register the highest CAGR of 12.63% during the forecast period.
Favorable Government Funding for Vaccine Development
The United States nearly spends USD 1.4 billion on vaccine R&D annually, with funds received from various sources. The most recent funding would be Government of Canada's funding to enhance vaccine research and development which amounts to $1 million.
It can be clearly seen that vaccines are of prime importance to the healthcare industry globally as there are many developing regions who are in dire need of vaccines and are a victim of lack of resources.
The Global Therapeutic Vaccines market is set to witness great growth opportunities in the recent times. This can be attributed to the growing awareness of communicable diseases and new threats, cost effectiveness of vaccines, development in new research techniques and increasing demand, new target population and emergence of developing markets
- Huge Capital Expenditures
- North America to Dominate the Market
- Neon Therapeutics and Vedantra Pharmaceutical partnered to develop therapeutic vaccine for cancer.
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
- Agenus Inc.
- Bavarian Nordic
- Cytos Biotechnology
- Dendreon Corp
- Merck Serono
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/dsjbvx/global?w=4